Lilly’s atopic dermatitis drug hits endpoints
admin 27th August 2019 Uncategorised 0Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
More: Lilly’s atopic dermatitis drug hits endpoints
Source: News
Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
More: Lilly’s atopic dermatitis drug hits endpoints
Source: News
© 1994 - 2024 B.M. Pharmaceuticals